Project Description

Extremely high-cost CAR-T immunotherapies, specifically Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel), are becoming more widely available worldwide despite the limited clinical data available at launch.

This study investigates whether the evidence for Kymriah and Yescarta for the diffuse large B-cell lymphoma (DLBCL) indication was sufficient to secure a positive outcome from HTA bodies in Europe and the USA, and how gaps in the current evidence are linked to access restrictions and mitigation strategies.

Read our findings here….(Evidence base for Yescarta and Kymriah)